# **RESEARCH ARTICLE**

# The application of enhanced recovery after surgery for upper gastrointestinal surgery: Meta-analysis

Zhen-Dong Huang<sup>1+</sup>, Hui-Yun Gu<sup>2+</sup>, Jie Zhu<sup>3</sup>, Jie Luo<sup>1</sup>, Xian-Feng Shen<sup>4</sup>, Qi-Feng Deng<sup>1</sup>, Chao Zhang<sup>1\*</sup> and Yan-Bing Li4\*

# Abstract

Background: Although enhanced recovery after surgery (ERAS) has made great progress in the field of surgery, the guidelines point to the lack of high-quality evidence in upper gastrointestinal surgery.

Methods: Randomized controlled trials in four electronic databases that involved ERAS protocols for upper gastrointestinal surgery were searched through December 12, 2018. The primary endpoints were lung infection, urinary tract infection, surgical site infection, postoperative anastomotic leakage and ileus. The secondary endpoints were postoperative length of stay, the time from end of surgery to first flatus and defecation, and readmission rates. Subgroup analysis was performed based on the type of surgery.

Results: A total of 17 studies were included. The results of the meta-analysis indicate that there was a decrease in rates of lung infection (RR = 0.50, 95%CI: 0.33 to 0.75), postoperative length of stay (MD = -2.53, 95%CI: -3.42 to - 1.65), time until first postoperative flatus (MD = -0.64, 95%Cl: - 0.84 to - 0.45) and time until first postoperative defecation (MD = -1.10, 95%Cl: -1.74 to -0.47) in patients who received ERAS, compared to conventional care. However, other outcomes were not significant difference. There was no significant difference between ERAS and conventional care in rates of urinary tract infection (P = 0.10), surgical site infection (P = 0.42), postoperative anastomotic leakage (P = 0.45), readmissions (P = 0.31) and ileus (P = 0.25).

**Conclusions:** ERAS protocols can reduce the risk of postoperative lung infection and accelerating patient recovery time. Nevertheless, we should also consider further research ERAS should be performed undergoing gastrectomy and esophagectomy.

Keywords: Enhanced recovery after surgery, Multimodal perioperative care, Upper gastrointestinal surgery, Gastric cancer, Postoperative morbidity

# Background

The concept of enhanced recovery after surgery (ERAS) [1] was first introduced by the pioneer surgeon H. Kehlet in 1997. ERAS has been of considerable interest to the field of medicine in recent years [2]. ERAS protocols were first applied in colorectal surgery [2], expanding

\* Correspondence: zhangchao0803@126.com; liyanbing126@163.com

<sup>4</sup>Department of General Surgery, Taihe Hospital, Hubei University of Full list of author information is available at the end of the article

gradually to obstetrics and gynaecology [3], urology [4], and pelvic surgery [5]. Multimodal perioperative care played a vital role in the ERAS protocols that were based on ERAS society guidelines [6]. Lower complication rates, faster gastrointestinal function recovery, faster free activity, lower average hospitalization costs and shorter postoperative hospital stays were observed in patients in the ERAS group. ERAS has adopted a series of measures to reduce the physical and psychological trauma that surgical patients experience, and these help the patients rapidly achieve functional recovery.

The upper part of the gastrointestinal tract includes the esophagus, stomach, and duodenum. A scientific

© The Author(s), 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Zhen-Dong Huang and Hui-Yun Gu are first author.

Medicine, No.32, South Renmin Road, Shiyan 442000, China







<sup>&</sup>lt;sup>1</sup>Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital,

Hubei University of Medicine, No.32, South Renmin Road, Shiyan 442000, China

paper about cases of cancer around the world [7] showed that digestive cancer has the highest morbidity and mortality rate of all cancers. Surgery is the mainstay of treatment for digestive cancer [8]. The purpose of surgery is to completely eliminate the primary tumour and to rebuild the digestive tract. Given that it is traumatic, surgery itself is the most common source of stress for surgical patients.

Even though a meta-analysis of observational studies of postoperative complication outcome [9] was done in 2017, it did not give a detailed list that classified the complications. A meta-analysis [10] in 2018 indicated that the ERAS protocol increased the rate of readmissions in elderly patients with gastric cancer, but this result requires more studies to confirmits findings, it is only for the analysis of Gastrectomy. In this metaanalysis, we conducted a comprehensive evaluation of the effect of ERAS on upper gastrointestinal surgery patients across RCTs. The aim of this study was to evaluate the impact of ERAS protocols for upper gastrointestinal surgery postoperative complications and postoperative recovery time for clinical ERAS practice and provide more evidence for the update of the guideline.

# Methods

# Literature search

We used the guidelines from the Preferred Reporting Items for Systematic Review and Meta-Analyses [11]. All studies were obtained by searching Ovid Medline, Ovid EMBASE, CENTRAL and ISIWeb of Science for articles that were published through December 12, 2018. Detailed search strategies are shown in Additional file 1.

# Inclusion and exclusion criteria

Studies were included when they met the following criteria: (1) human patients undergoing gastric surgery, esophagectomy or duodenectomy; (2) intervention used: ERAS protocols; (3) comparison: conventional care; (4) outcomes evaluated: postoperative lung infection (LI), postoperative urinary tract infection (UTI), postoperative surgical site infection (SSI), postoperative anastomotic leakage and ileus, readmission rate, postoperative length of stay (PLOS), time from surgery to first flatus and defecation; types of postoperative complications according to original study authors' definition (5) study design: RCTs. No minimum sample size or minimum number of ERAS process measures was required for inclusion. Studies were excluded for the following reasons: (1) non-full-text English article; (2) emergency surgery; (3) sleeve gastrectomy for obesity; (4) data was inadequate for meta-analysis; (5) ERAS protocols that were not followed for the entire perioperative period.

# Data extraction and quality assessment

According to the inclusion and exclusion criteria, two authors (ZDH and QFD) independently selected the studies to be included by reading abstracts and full-text articles. If a disagreement arose due to inconsistent understanding, then consensus was reached by arbitration and discussion with a third investigator. Information and data were extracted by two independent authors (XFS and YF) and checked for accuracy by a third investigator (CZ). The following information was extracted from all of the trials: first author, year of publication, patients' characteristics (i.e., age and sex), surgical type, ERAS protocol interventions, and follow-up time. Primary endpoints for the study included major incidents of the following complications: LI, UTI, SSI, postoperative anastomotic leakage and ileus. Secondary endpoints were PLOS, the time until intestinal function recovery (i.e., time until the first flatus and defecation), and readmission rates.

Two authors (ZDH and QFD) independently assessed the risk of biasin accordance with the Cochrane risk of bias tool [12]. The risk of bias in each item was graded as "high risk", "low risk" or "unclear".

#### Statistical analysis

Statistical meta-analysis was performed with R software (meta software package). The Doi plots [13] were drawn by MetaXL (Version 5.3). Pooled risk ratios (RR) with 95% confidence intervals (CI) wereapplied to analyse dichotomous data; continuous data were analysed as the mean difference (MD) with a 95%CI. However, many studies only reported the median and range of the samples or the first and third quartiles. In these cases, we needed to estimate the sample mean and SD [14, 15]. We used the converted sample mean and SD for metaanalysis. I<sup>2</sup> [16] statistics were used to assess the heterogeneity of each analysis. If  $I^2 > 40$  [16], we assumed that there was statistical heterogeneity. Meanwhile, the pooled effect size was calculated by the random effects model (REM). For studies with zero events in their arms, this was done by adding a fixed value (typically 0.5) to all cells [17]. Subgroup analysis was performed based on the type of cancer, surgical procedure and scope of gastrectomy.

Doi plots were used to evaluate the data for possible publication bias. Doi plots are a new method of graphing that are used to detectpossible publication bias and have a higher sensitivity than funnel plots. An LFK index within  $\pm 1$  indicates that the Doi plots haveno asymmetry; when the LFK index exceeds  $\pm 1$  but is within  $\pm 2$ , it indicates that the Doi plots have minor asymmetry; when the LFK index exceeds  $\pm 2$ , it suggests that there is major asymmetry.

### Results

# Literature identification

Ovid Medline, Ovid EMBASE, CENTRAL and Web of Science were systematically searched through December 12, 2018. The search resulted in 2885 articles. After initial evaluation, 597 studies were removed for being duplicates, 2204 for being irrelevant (as determined by reading the abstracts), and 67 studies were excluded for reasons determined by reading the full text (Additional file 2). 16 studies [18–33] were included in the final meta-analysis. Figure 1 shows the work flow for the selection of studies.

# Study and ERAS characteristics

Studies were included in the meta-analysis when they adhered to consensus guidelines for ERAS protocols [6, 34]. The basic characteristics of the included studies are shown in Table 1. Table 2 shows the details of the key elements of ERAS protocols for all of the studies, including the type of disease and the surgical site. It also summarizes ERAS protocol items, and it details the primary endpoints and follow-up times. Two studies reported comparing laparoscopic to open surgery [19, 23]; the other reported on patients aged 45 to 74 years and 75 to 89 years [21]. Finally, a total of 19 RCTs from 16 studies, included 1830 patients, of whom 907 were in the ERAS arm and 923 were in the control arm, were found to be studies that compared ERAS to conventional care. Gastric cancer surgery was reported in 14 RCTs from 11 studies, and esophagectomy was reported in 5 studies.

#### **Quality assessment**

The results of the quality assessment are shown in Additional file 3. It is notable that none of the 19 RCTs can blind the surgeon or the patient during the surgery. In addition, all 19 RCTs were quite similar in their risk of bias. Nine of the RCTs did not report random sequence generation, only 2 RCTs had blinded outcome assessments.

# **Primary outcomes**

# Lung infection

Fifteen RCTs including 1496 patientsreported postoperative LI. Pooling the resultssuggested that ERAS protocols significantly decreased the incidence of postoperative LI compared to conventional care (Fig. 2, RR = 0.50, 95%CI:



Study	Year	Sample (	(n)	Age (years)		Sex, male/	female	Follow-
		ERAS	CC	ERAS	CC	ERAS	CC	up (weeks)
Wang [18]	2010	45	47	58.8 ± 9.7	56.9 ± 9.1	32/13	29/18	4
Chen [LS] [19]	2012	19	22	59(49–71)	62.5(45-72)	10/9	10/12	4
Chen [OS] [19]	2012	21	20	62.5(45–72)	64.5(49–75)	9/12	12/8	4
Feng [20]	2013	59	60	55 ± 11.4	55.8 ± 10.1	41/18	44/16	4
Bu [45-74y] [21]	2015	64	64	62.4 ± 7.8	$63 \pm 7.4$	31/33	35/29	4
Bu [75-89y] [21]	2015	64	64	80.1 ± 4	79.6 ± 3.5	37/27	40/24	4
Abdikarim [22]	2015	30	31	63 ± 12	62±11	21/9	20/11	4
Liu [LS] [23]	2016	21	21	69.2 ± 5.1	$70.3 \pm 5.8$	10/11	12/9	4
Liu [OS] [ <mark>23</mark> ]	2016	21	21	67.8 ± 3.9	68.6 ± 4.9	9/12	11/10	4
Fujikuni [24]	2016	40	40	< 70(29), ≥70(11)	< 70(28), ≥70(12)	20/20	24/16	4
Tanaka [25]	2017	73	69	68(29–85)	67(44–85)	49/24	49/20	4
Xia [26]	2017	73	76	61 (40–75)	63 (35–75)	48/25	50/26	4
Wu [27]	2017	34	41	$63.74 \pm 9.56$	$62.93 \pm 9.44$	25/9	31/10	NR
Kim [28]	2012	22	22	52.6 ± 11.69	57.5 ± 14.5	13/9	15/7	2
Zhao [29]	2014	34	34	55.14 ± 10.65	57.86 ± 11.34	27/7	25/9	4
Chen [30]	2016	128	132	56.34±13.28	55.72 ± 10.34	103/25	106/26	4
Li [31]	2017	55	55	$67.73 \pm 6.69$	67 ± 5.58	38/17	41/14	8
Zhang [32]	2017	47	47	45–76	45–75	28/19	25/22	12
Zhang [33]	2018	57	57	66.89±13.45	67.01 ± 12.78	39/18	38/19	NR

Table 1 Main characteristics of the included studies

Note: ERAS Enhacned recovery after surgery, CC Conventional care, LS Laparoscopic surgery, OS Open surgery, NR Not reported; 45-74y: Patients aged 45–74 years; 75-89y: Patients aged 75–89 years

0.33 to 0.75). The test of heterogeneity ( $I^2 = 0\%$ ) indicated that there was little heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated that the incidence of LI after surgery was significantly decreased by using ERAS protocols (Fig. 2, RR = 0.57, 95%CI: 0.34 to 0.95,  $I^2 = 0$ %). Among RCTs performed in the area of esophagectomies, the incidence of LI after surgery was significantly reduced by using ERAS protocols (Fig. 2, RR = 0.41, 95%CI: 0.21 to 0.79,  $I^2 = 0$ %). However, based on subgroup analyses of the surgical procedure and scope of gastrectomy, Table 3 showed that there were no statistical differences in all subgroup analyses of LI.

# Urinary tract infection

Ten RCTs included 824 patients diagnosed with postoperative UTI. Pooling the results suggested that ERAS protocols did not increase the incidence of urinary tract infection compared to conventional care (Fig. 3, RR = 0.59, 95% CI: 0.31 to 1.11). The test of heterogeneity (I<sup>2</sup> = 0%) indicated that there was little heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated that the incidence of postoperative

UTI was not increased by ERAS protocols (Fig. 3, RR = 0.60, 95%CI: 0.31 to 1.16,  $I^2 = 0\%$ ). There were too few RCTs about esophagectomies to calculate incidence of postoperative UTI in this area. However, the results of subgroup analyses of UTI based on the surgical procedure and scope of gastrectomy were no statistical differences in Table 3.

# Surgical site infection

Fifteen RCTs included 1555 patients who reported postoperative SSI. Pooling the resultssuggested that ERAS protocols did not increase the incidence of postoperative SSI compared to conventional care (Fig. 4, RR = 0.80, 95%CI: 0.47 to 1.37). The test of heterogeneity ( $I^2 = 0\%$ ) indicated that there was little heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated that the incidence of SSI after surgery was not increased by ERAS protocols (Fig. 4, RR = 0.86, 95%CI: 0.46 to 1.61,  $I^2 = 0\%$ ). Among RCTs performed in the area of esophagectomiesy surgery, the incidence of SSI was not increased (Fig. 4, RR = 0.67, 95%CI: 0.24 to 1.86,  $I^2 = 0\%$ ). However, Table 3 demonstrated that there were no statistical differences in all subgroup

	000000000000000000000000000000000000000			2			
Author, Year	Surgery	Disease	I N Enhanced Recover	y After Surgery I	nterventions		Number of item
			0 2 3 4 6			0 0	using ekas
Wang 2010 [18]	Gastrectomy	Gastric Cancer	E 45 🖌 🖌 🆌 🇸	~ ~	/ / / / /	~ ~	14
			C 47				
Chen (LS) 2012 [1 <mark>9</mark> ]	Distal Gastrectomy	Gastric Cancer	E 19 1 1 1 1	~ ~	/ / / /	`` `	12
			C 22 🖌	>			
Chen (OS) 2012 [19]	Distal Gastrectomy	Gastric Cancer	E 21 1 1 1 1	>	~ ~ ~	`` `	10
			C 20				
Feng 2013 [ <mark>20</mark> ]	Radical	Gastric Cancer	E 59 🖌 🖌	` `	` `	` `	ø
	gastrectomy		C 60				
Bu (45-74y) 2015 [ <b>2</b> 1]	Gastrectomy	Gastric Cancer	E 64 🖌 🖌 🖌	~ ~ ~	~ ~ ~ ~	` `	12
			C 64 🖌	>			
Bu (75-89y) 2015 [ <b>2</b> 1]	Gastrectomy	Gastric Cancer	E 64 🖌 🖌 🖌	~ ~ ~	~ ~ ~ ~	`` `	12
			C 64 🖌	>			
Abdikarim 2015 [22]	Radical	Stomach Carcinomas	E 30 1 1 1 1	~ ~	>	`` `	6
	gastrectomy		C 31 🖌	>			
Liu (LS) 2016 [ <mark>23</mark> ]	Radical	Gastric Cancer	E 21 🖌 🖌	~ ~ ~	~ ~	`` `	6
	gastrectomy		C 21	>			
Liu (OS) 2016 [ <mark>23</mark> ]	Radical	Gastric Cancer	E 21 🖌 🖌	` `	~ ~	` `	œ
	gastrectomy		C 21				
Fujikuni 2016 [ <mark>24</mark> ]	Gastrectomy	Gastric Cancer, Submucosal Tumor	E 40 🗸	>	~	>	4
			C 40	>			
Tanaka 2017 [ <mark>25</mark> ]	Gastrectomy	Gastric Cancer	E 73 🗸 🗸	~ /	>	` `	7
			C 69	>		>	
Xia 2017 [ <mark>26</mark> ]	Radical	Gastric Cancer	E 73 🖌 🖌 🗸	~ ~	~ ~ ~ ~ ~	` `	12
	Gastrectomy		C 76	>			
Wu 2017 [ <mark>27</mark> ]	Distal Gastrectomy	Gastric Cancer	E 34 🖌 🖌 🗸	>	~ ~ ~ ~	`` `	10
			C 41				
Kim 2012 [ <mark>28</mark> ]	Distal Gastrectomy	Gastric Cancer	E 22 🖌 🖌 🗸	~ ~	~ ~ /	` `	10
			C 22 🗸	~ ~	`		
Zhao 2014 [ <mark>29</mark> ]	Esophagectomy	Esophageal Cancer	E 34 🖌 🖌 🖌	>	· · / /	~ ~	10
			C 34 🖌				
Chen 2016 [ <b>30</b> ]	Esophagectomy	Esophageal Cancer	E 128 🖌 🖌	>	//////	` `	10
			C 132 🖌				

Table 2 The Iten	ns of Characteristics	of Included Studies from Enhanced Recovery Afte	er Surgery	(ERAS) and C	Controls (Continue	()			
Author, Year	Surgery	Disease	z –	Enhanced Rec	covery After Surgery	Interventions			Number of item
				0 0 0	<ul> <li>()</li> <li>(</li></ul>	8 9 8 6	9 9 0	@ 6) @	using ERAS
Li 2017 [31]	Esophagectomy	Esophageal Cancer	E 55	>	>	>	>	>	5
			C 55		>				
Zhang 2017 [ <b>32</b> ]	Esophagectomy	Esophageal Cancer combined with Metabolic	E 47	>	>			~ / /	5
		Syndrome	C 47		>				
Zhang 2018 [ <b>33</b> ]	Esophagectomy	Esophageal Carcinoma	E 57	~ ~ /	>	>	>	>	7
			C 57	`	>				
			C 37	` `		~ ~			

Note: *E/ERAS* Enhacned recovery after surgery, *C* Conventional care, *LS* Laparoscopic surgery, *OS* Open surgery, *45*-74y. Patients aged *45*-74 years; *75*-89y. Patients aged *75*-89y years; I: Intervention, PLOS: Postoperative length of hospital stays; N: Number of patients; Enhanced Recovery After Surgery items: OPreoperative counselling; OAvoid Bowel preparation; OPreoperative Carbohydrate; ONo Preanesthetic Medication; Entity of hospital stays; N: Number of patients; Enhanced Recovery After Surgery items: OPreoperative counselling; OAvoid Bowel preparation; OPreoperative Carbohydrate; ONo Preanesthetic Medication; Entity of hospital stays; N: Number of patients; Enhanced Recovery After Surgery; OPreoperative counselling; OAvoid Bowel preparation; OPreoperative Carbohydrate; ONo Preanesthetic Medication; Entity on boto presention; Entity of the prophylaxis; OMinimal Invasive Surgery; OPreoperative intubation; OPvoid Postoperative nausea and vomiting; OEpidural analgesia; OPvoiding hypothermia; OFluid balance; @Avoid Peritoneal Drainage; Early Urinary drainage; Removal; OPreoperative nausea movement; OFarly Oral Feeding; Early Urinary drainage; Early Urinary drainage; Entervala; Carbohydrate; OPvoid Postoperative novement; OFarly Oral Feeding; Early Urinary drainage; Defining hypothermia; Definid balance; OPvoid Peritoneal Drainage; Defining Removal; OPvoid Properative novement; OFarly Oral Feeding; Early Urinary drainage; Defining the properative novement; OFArly Oral Feeding; Early Urinary drainage; OPvoiding Analgesia; OPvoid Powel movement; OFArly Oral Feeding; Early Urinary drainage Removal; Sectional Analgesia; OPvoid Powel Movement; Defining Oral Feeding; Powel Movement; Defining the properative of the properative of

esophagectomy         Zhao 2014       0       34       1       34       1       34         Chen 2016       3       128       4       132       0.33       [0.01; 7.90]       2.3%       1.79         Chen 2016       3       128       4       132       0.80       [0.20; 3.17]       6.7%       8.99         Li 2017       3       55       12       55       0.28       [0.09; 0.86]       19.0%       13.29         Zhang 2017       1       47       5       47       0.27       [0.05; 1.59]       8.4%       5.49         Prixed effect model       321       325       0.41       [0.21; 0.79]       43.2%          Random effects model       321       325       0.41       [0.21; 0.82]        36.69         Wang 2010       0       45       1       47       0.35       [0.01; 8.32]       2.2%       1.79         Chen(LS) 2012       0       21       1       20       0.38       [0.02; 8.91]       2.1%       1.79         Bu(45-74y) 2015       2       64       6       64       0.33       [0.02; 1.40]       15.8%       1.79         Bu(45-74y) 2015	Study	Experim Events	nental Total	Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
Zhao 2014       0       34       1       34        0.33 $[0.01; 7.90]$ 2.3% $1.79$ Chen 2016       3       128       4       132        0.80 $[0.02; 3.17]$ $6.7\%$ $8.99$ Li 2017       3       55       12       55 $0.80$ $[0.02; 3.17]$ $6.7\%$ $8.99$ Zhang 2017       1 $47$ $547$ $0.28$ $[0.09; 0.86]$ $19.0\%$ $13.29$ Zhang 2018       2 $57$ $4$ $57$ $0.56$ $[0.12; 2.50]$ $6.8\%$ $7.49$ Random effects model $321$ $325$ $0.41$ $[0.21; 0.79]$ $43.2\%$ $$ gastrectomy       Wang 2010 $0$ $45$ $1$ $47$ $ 0.35$ $[0.02; 8.91]$ $2.1\%$ $1.79$ Chen(LS) 2012 $0$ $21$ $1$ $22$ $0.35$ $[0.02; 8.91]$ $2.3\%$ $1.79$ Bu( $45-74y$ ) $2015$ $5$ $64$ $7$ $64$ $0.38$ $[0.02; 8.91]$ $2.3\%$ $1.79$	esophagectomy					e E				
Chen 2016       3       128       4       132       0.80       0.20; 3.17]       6.7%       8.99         Li 2017       3       55       12       55       0.80       0.20; 3.17]       6.7%       8.99         Zhang 2017       1       47       5       47       0.27       0.05; 1.59]       8.4%       5.49         Fixed effect model       321       325       0.56       0.12; 2.50       6.8%       7.49         Random effects model       321       325       0.56       0.12; 2.50       6.8%       7.49         Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 0.78$ 325       0.41       0.21; 0.82        36.69         Mang 2010       0       45       1       47       0.35       0.01; 8.32]       2.2%       1.79         Chen(LS) 2012       0       1       1       20       0.38       0.02; 8.91]       2.1%       1.79         Bu(45-74y) 2015       2       64       6       64       0.38       0.09; 1.59]       9.9%       8.39         Bu(75-89y) 2015       5       64       7       64       0.33       0.01; 7.73]       2.3%       1.79         Tanaka 2017       1       73	Zhao 2014	0	34	1	34 -		0.33	[0.01; 7.90]	2.3%	1.7%
Li 2017       3       55       12       55       0.28       0.09;       0.86       19.0%       13.29         Zhang 2017       1       47       5       47       0.27       [0.05;       1.59]       8.4%       5.49         Zhang 2018       2       57       4       57       0.27       [0.05;       1.59]       8.4%       5.49         Fixed effect model       321       325       0.41       [0.21;       0.79]       43.2%        0.42       [0.21;       0.86]       19.0%       13.29         gastrectomy       Wang 2010       0       45       1       47        0.35       [0.01;       8.32]       2.2%       1.79         Chen(LS) 2012       0       21       1       20       0.38       [0.02;       8.91]       2.1%       1.79         Bu(45-74y) 2015       2       64       6       64       0.38       [0.09;       15.8%       17.99         Bu(45-789y) 2015       5       64       7       64       0.73       [0.26;       2.81       1.1%       15.49         Liu(OS) 2016       0       21       1       21       0.33       [0.01;       7.33	Chen 2016	3	128	4	132		0.80	[0.20; 3.17]	6.7%	8.9%
Zhang 2017       1       47       5       47       0.27       [0.05; 1.59]       8.4%       5.49         Zhang 2018       2       57       4       57       0.56       [0.12; 2.50]       6.8%       7.49         Fixed effect model       321       325       0.41       [0.21; 0.79]       43.2%          Random effects model       1       47       47        0.42       [0.21; 0.82]        36.69         gastrectomy       Wang 2010       0       45       1       47        0.35       [0.01; 8.32]       2.2%       1.79         Chen(LS) 2012       0       1       22        0.38       [0.02; 8.91]       2.1%       1.79         Bu(45-74y) 2015       2       64       64        0.33       [0.02; 48.14]       0.8%       1.19         Liu(OS) 2016       0       21       1       21        0.33       [0.01; 7.73]       2.3%       1.79         Tanaka 2017       1       73       1       69        0.33       [0.01; 7.73]       2.3%       1.79         Fixed effect model       421       429        0.50	Li 2017	3	55	12	55	- + <u>i</u>	0.28	[0.09; 0.86]	19.0%	13.2%
Zhang 2018       2       57       4       57         Fixed effect model       321       325       0.56 $[0.12; 2.50]$ $6.8\%$ $7.4\%$ Random effects model       321       325       0.41 $[0.21; 0.79]$ $43.2\%$ gastrectomy       Wang 2010       0       45       1       47       0.35 $[0.01; 8.32]$ 2.2%       1.7%         Chen(LS) 2012       0       19       1       22       0.38 $[0.02; 8.91]$ 2.1%       1.7%         Chen(OS) 2012       0       21       1       20       0.38 $[0.02; 8.91]$ 2.1%       1.79         Bu(45-74y) 2015       2       64       6       64       0.38 $[0.09; 1.59]$ 9.9% $8.39$ Bu(75-89y) 2015       5       64       7       64       1.14 $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $1.4\%$ $0.33$ $[0.01; 7.36]$ $2.3\%$ $1.7\%$ Bu(45-74y) 2015       2       64	Zhang 2017	1	47	5	47		0.27	[0.05; 1.59]	8.4%	5.4%
Fixed effect model       321       325       0.41 [0.21; 0.79]       43.2%          Random effects model $1^2 = 0\%, \tau^2 = 0, p = 0.78$ 0.42 [0.21; 0.82]        36.69         gastrectomy       Wang 2010       0       45       1       47        0.42 [0.21; 0.82]        36.69         Wang 2010       0       45       1       47        0.35 [0.01; 8.32]       2.2%       1.79         Chen(LS) 2012       0       21       1       20       0.38 [0.02; 8.91]       2.1%       1.79         Geng 2013       5       59       10       60        0.38 [0.09; 1.59]       9.9%       8.39         Bu(45-74y) 2015       2       64       6       64        0.38 [0.09; 1.59]       9.9%       8.39         Bu(V5-89y) 2015       5       64       7       64        0.38 [0.02; 48.14]       0.8%       1.19         Liu(CS) 2016       0       21       1       21       1.69       0.33 [0.01; 7.73]       2.3%       3.79         Heterogeneity: $l^2 = 0\%, \tau^2 = 0, p = 1.00$ Fixed effect model       421       429       0.50 [0.33; 0.75]       0.50       0.53; 0.97]	Zhang 2018	2	57	4	57		0.56	[0.12; 2.50]	6.8%	7.4%
Random effects model $0.42 [0.21; 0.82]$ $$ $36.69$ Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 0.78$ $0.42 [0.21; 0.82]$ $$ $36.69$ gastrectomy       Wang 2010 $0.45$ $1.47$ $0.35 [0.01; 8.32]$ $2.2\%$ $1.79$ Chen(LS) 2012 $0.21$ $1.20$ $0.38 [0.02; 8.91]$ $2.1\%$ $1.79$ Feng 2013 $5.59$ $10.60$ $0.38 [0.02; 1.40]$ $15.8\%$ $17.99$ Bu(45-74y) 2015 $2.64$ $6.64$ $0.38 [0.09; 1.59]$ $9.9\%$ $8.39$ Bu(75-89y) 2015 $5.64$ $7.64$ $0.33 [0.01; 7.73]$ $2.3\%$ $1.79$ Liu(CS) 2016 $0.21$ $0.21$ $0.21$ $0.21$ $0.33 [0.01; 7.73]$ $2.3\%$ $1.19$ Liu(OS) 2016 $0.21$ $1.21$ $0.33 [0.01; 7.73]$ $2.3\%$ $1.79$ Tanaka 2017 $1.73$ $1.69$ $0.57 [0.34; 0.95]$ $56.8\%$ $$ Random effects model       421       429 $0.57 [0.34; 0.95]$ $56.8\%$ $$ Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ $\tau^2 = 0$ , $\tau^2 = 0$ , $p = 1.00$ $0.5$	Fixed effect model		321		325		0.41	[0.21; 0.79]	43.2%	
Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 0.78$ gastrectomy         Wang 2010       0       45       1       47       0.35       [0.01; 8.32]       2.2%       1.79         Chen(LS) 2012       0       21       1       20       0.35       [0.01; 7.36]       2.3%       1.79         Chen(OS) 2012       0       21       1       20       0.35       [0.01; 7.36]       2.3%       1.79         Su(45-74y) 2015       2       64       6       64       0.33       [0.02; 1.40]       15.8%       17.99         Bu(45-74y) 2015       5       64       7       64       0.33       [0.02; 48.14]       0.8%       1.19         Liu(LS) 2016       0       21       1       21       0.33       [0.01; 7.73]       2.3%       1.79         Tanaka 2017       1       73       1       69       0.35       [0.01; 7.73]       2.3%       3.39         Wu 2017       3       34       5       41       9       0.57       [0.34; 0.95]       56.8%          Fixed effect model       742       754       0.50       [0.33; 0.75]       100.0%        0.52       [0.34; 0.	Random effects model						0.42	[0.21; 0.82]		36.6%
gastrectomy         Wang 2010       0       45       1       47 $\bullet$ 0.35       [0.01; 8.32]       2.2%       1.7%         Chen(LS) 2012       0       21       1       20 $\bullet$ 0.35       [0.01; 8.32]       2.2%       1.7%         Chen(OS) 2012       0       21       1       20 $\bullet$ 0.35       [0.01; 7.36]       2.3%       1.7%         Feng 2013       5       59       10       60 $\bullet$ 0.33       [0.02; 8.91]       2.1%       1.7%         Bu(45-74y) 2015       2       64       6       64 $\bullet$ 0.33       [0.02; 1.40]       15.8%       17.9%         Bu(75-89y) 2015       5       64       7       64 $\bullet$ 0.33       [0.09; 1.59]       9.9%       8.3%         Liu(LS) 2016       0       21       1       21 $\bullet$ 1.00       [0.02; 48.14]       0.8%       1.1%         Liu(OS) 2016       0       21       1       21 $\bullet$ 0.33       [0.01; 7.73]       2.3%       3.3%         Wu 2017       3       34       5       41 $\bullet$ $\bullet$ $\bullet$ $\bullet$	Heterogeneity: $I^2 = 0\%$ , $\tau^2$	= 0, p = 0	).78							
Wang 2010045147 $\bullet$ 0.35[0.01; 8.32]2.2%1.79Chen(LS) 20120211200.38[0.02; 8.91]2.1%1.79Chen(OS) 20120211200.32[0.01; 7.36]2.3%1.79Feng 201355910600.38[0.02; 8.91]2.1%1.79Bu(45-74y) 2015264664 $\bullet$ 0.38[0.09; 1.59]9.9%8.39Bu(75-89y) 2015564764 $\bullet$ 0.73[0.26; 2.08]11.4%15.4%Liu(LS) 2016021021 $\bullet$ 1.00[0.02; 48.14]0.8%1.1%Liu(OS) 2016021121 $\bullet$ 0.33[0.01; 7.73]2.3%1.79Tanaka 2017173169 $\bullet$ 0.35[0.10; 8.88]2.3%3.39Wu 2017334541 $\bullet$ 0.77[0.22; 2.70]7.6%10.59Fixed effect model421429 $\bullet$ 0.57[0.33; 0.75]100.0%Heterogeneity: $l^2 = 0\%, \tau^2 = 0, p = 1.00$ $\bullet$ $\bullet$ 0.50[0.33; 0.75]100.0%Fixed effect model742754 $\bullet$ 0.50[0.33; 0.75]100.0%0.52[0.34; 0.78]100.0%100.0%	gastrectomy									
Chen(LS) 2012019122 $1$ $0.38$ $[0.02; 8.91]$ $2.1\%$ $1.79$ Chen(OS) 2012021120 $0.32$ $[0.01; 7.36]$ $2.3\%$ $1.79$ Feng 20135591060 $0.32$ $[0.01; 7.36]$ $2.3\%$ $1.79$ Bu(45-74y) 2015264664 $0.38$ $[0.02; 1.40]$ $15.8\%$ $17.9\%$ Bu(75-89y) 2015564764 $0.38$ $[0.09; 1.59]$ $9.9\%$ $8.3\%$ Liu(LS) 2016021021 $1.14\%$ $15.4\%$ Liu(OS) 2016021121 $1.00$ $[0.02; 48.14]$ $0.8\%$ $1.1\%$ Tanaka 2017173169 $0.33$ $[0.01; 7.73]$ $2.3\%$ $3.3\%$ Wu 2017334541 $0.77$ $[0.22; 2.70]$ $7.6\%$ $10.5\%$ Fixed effect model421429 $0.57$ $[0.34; 0.95]$ $56.8\%$ $$ Random effects model742754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ Fixed effect model742754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ Random effects model742754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ 0.52 $[0.34; 0.78]$ $$ $100.0\%$ $$ $0.52$ $0.34; 0.78]$ $$	Wang 2010	0	45	1	47 -		0.35	[0.01; 8.32]	2.2%	1.7%
Chen(OS) 20120211200.32 $[0.01; 7.36]$ 2.3% $1.79$ Feng 201355910600.33 $[0.20; 1.40]$ $15.8\%$ $17.99$ Bu(45-74y) 20152646640.38 $[0.09; 1.59]$ $9.9\%$ $8.39$ Bu(75-89y) 20155647640.38 $[0.09; 1.59]$ $9.9\%$ $8.39$ Liu(LS) 20160210211 $1.4\%$ $15.4\%$ Liu(OS) 2016021121 $1.00$ $[0.02; 48.14]$ $0.8\%$ $1.19$ Tanaka 2017173169 $0.33$ $[0.01; 7.73]$ $2.3\%$ $1.79$ Tanaka 2017173169 $0.95$ $[0.10; 8.88]$ $2.3\%$ $3.39$ Wu 2017334541 $0.77$ $[0.22; 2.70]$ $7.6\%$ $10.59$ Fixed effect model421429 $0.57$ $[0.34; 0.95]$ $56.8\%$ $$ Random effects model742754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ Fixed effect model742754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ Random effects model742754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ $0.52$ $[0.34; 0.78]$ $$ $100.0\%$ $$ $0.52$ $0.34; 0.78]$ $$	Chen(LS) 2012	0	19	1	22		0.38	[0.02; 8.91]	2.1%	1.7%
Feng 20135591060Bu(45-74y) 2015264664Bu(75-89y) 2015564764Liu(LS) 2016021021Liu(OS) 2016021121Tanaka 2017173169Wu 2017334541Fixed effect model4214290.37Random effects model7427540.50Fixed effect model7427540.50Fixed effect model7427540.500.50[0.33; 0.75]100.0%0.52[0.34; 0.78]100.0%	Chen(OS) 2012	0	21	1	20 -		0.32	[0.01; 7.36]	2.3%	1.7%
Bu(45-74y) 2015       2       64       6       64       0.38       [0.09; 1.59]       9.9%       8.39         Bu(75-89y) 2015       5       64       7       64       0.73       [0.26; 2.08]       11.4%       15.49         Liu(LS) 2016       0       21       0       21       1.00       [0.02; 48.14]       0.8%       1.19         Liu(OS) 2016       0       21       1       21       0.33       [0.01; 7.73]       2.3%       1.79         Tanaka 2017       1       73       1       69       0.95       [0.10; 8.88]       2.3%       3.39         Wu 2017       3       34       5       41       0.77       [0.22; 2.70]       7.6%       10.59         Fixed effect model       421       429       0.57       [0.34; 0.95]       56.8%          Random effects model       742       754       0.50       [0.33; 0.75]       100.0%          Fixed effect model       742       754       0.50       [0.33; 0.75]       100.0%          0.52       [0.34; 0.78]        100.0%        100.0%	Feng 2013	5	59	10	60		0.53	[0.20; 1.40]	15.8%	17.9%
Bu(75-89y) 2015       5       64       7       64       0       0       0       1       15.4%         Liu(LS) 2016       0       21       0       21       1.00       0.02; 48.14]       0.8%       1.1%         Liu(OS) 2016       0       21       1       21       0.33       0.01; 7.73]       2.3%       1.7%         Tanaka 2017       1       73       1       69       0.95       0.10; 8.88]       2.3%       3.3%         Wu 2017       3       34       5       41       0.77       0.22; 2.70]       7.6%       10.5%         Fixed effect model       421       429       0.57       0.34; 0.95]       56.8%          Random effects model       742       754       0.50       0.53; 0.75]       100.0%          Fixed effect model       742       754       0.50       0.52       0.34; 0.78]        100.0%	Bu(45-74y) 2015	2	64	6	64		0.38	[0.09; 1.59]	9.9%	8.3%
Liu(LS) 2016       0       21       0       21       1.00       [0.02; 48.14]       0.8%       1.19         Liu(OS) 2016       0       21       1       21        0.33       [0.01; 7.73]       2.3%       1.79         Tanaka 2017       1       73       1       69       0.95       [0.10; 8.88]       2.3%       3.39         Wu 2017       3       34       5       41        0.77       [0.22; 2.70]       7.6%       10.59         Fixed effect model       421       429        0.57       [0.34; 0.95]       56.8%          Random effects model       742       754        0.50       [0.33; 0.75]       100.0%          Fixed effect model       742       754        0.50       [0.33; 0.75]       100.0%          Random effects model       742       754        0.50       [0.33; 0.75]       100.0%	Bu(75-89y) 2015	5	64	7	64		0.73	[0.26; 2.08]	11.4%	15.4%
Liu(OS) 2016       0       21       1       21       •••       0.33       [0.01; 7.73]       2.3%       1.79         Tanaka 2017       1       73       1       69       0.95       [0.10; 8.88]       2.3%       3.39         Wu 2017       3       34       5       41       0.77       [0.22; 2.70]       7.6%       10.59         Fixed effect model       421       429       0.57       [0.34; 0.95]       56.8%          Random effects model       742       754       0.50       [0.33; 0.75]       100.0%          Fixed effect model       742       754       0.50       [0.33; 0.78]        100.0%	Liu(LS) 2016	0	21	0	21		1.00	[0.02; 48.14]	0.8%	1.1%
Tanaka 2017       1       73       1       69       0.95 $0.10; 8.88]$ 2.3%       3.39         Wu 2017       3       34       5       41       0.77 $0.22; 2.70]$ 7.6% $10.59$ Fixed effect model       421       429       0.57 $0.34; 0.95]$ $56.8\%$ Random effects model       421       429       0.58 $0.35; 0.97]$ $63.4\%$ Heterogeneity: $l^2 = 0\%, \tau^2 = 0, p = 1.00$ 742       754       0.50 $0.50; 0.33; 0.75]$ $100.0\%$ Fixed effect model       742       754       0.50 $0.52; 0.34; 0.78]$ $100.0\%$	Liu(OS) 2016	0	21	1	21 -		0.33	[0.01; 7.73]	2.3%	1.7%
Wu 2017       3       34       5       41       0.77 $[0.22; 2.70]$ 7.6% $10.5\%$ Fixed effect model       421       429 $0.57$ $[0.34; 0.95]$ $56.8\%$ $$ Random effects model       421       429 $0.57$ $[0.34; 0.95]$ $56.8\%$ $$ Fixed effect model       742       754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ Fixed effects model       742       754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$ Random effects model       742       754 $0.50$ $[0.33; 0.75]$ $100.0\%$ $$	Tanaka 2017	1	73	1	69		0.95	[0.10; 8.88]	2.3%	3.3%
Fixed effect model       421       429 $0.57$ [ $0.34$ ; $0.95$ ] $56.8\%$ $$ Random effects model $0.57$ [ $0.34$ ; $0.95$ ] $56.8\%$ $$ Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ $0.50$ [ $0.33$ ; $0.75$ ] $0.0\%$ $$ Fixed effect model $742$ $754$ $0.50$ [ $0.33$ ; $0.75$ ] $100.0\%$ $$ Random effects model $0.52$ [ $0.34$ ; $0.78$ ] $$ $100.0\%$ $$	Wu 2017	3	34	5	41		0.77	[0.22; 2.70]	7.6%	10.5%
Random effects model       0.58 [0.35; 0.97]        63.4%         Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ 0.50 [0.33; 0.75]       100.0%          Fixed effect model       742       754       0.50 [0.33; 0.75]       100.0%          Random effects model       0.52 [0.34; 0.78]        100.0%        100.0%	Fixed effect model		421		429	$\Leftrightarrow$	0.57	[0.34; 0.95]	56.8%	
Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$ Fixed effect model       742       754         Random effects model       0.50       [0.33;       0.75]       100.0%          0.52       [0.34;       0.78]        100.0%	Random effects model					-	0.58	[0.35; 0.97]		63.4%
Fixed effect model         742         754         0.50         [0.33;         0.75]         100.0%            Random effects model         0.52         [0.34;         0.78]          100.0%	Heterogeneity: $I^2 = 0\%$ , $\tau^2$	= 0, <i>p</i> = 1	.00							
Random effects model 0.52 [0.34; 0.78] 100.0%	Fixed effect model		742		754		0.50	[0.33; 0.75]	100.0%	
Heterogeneity: $l^2 = 0\%$ , $\tau^2 = 0$ , $p = 1.00$	<b>Random effects model</b> Heterogeneity: $I^2 = 0\% \tau^2$	= 0, p = 1	.00				0.52	[0.34; 0.78]		100.0%
Residual heterogeneity: $l^2 = 0\%$ , $p = 1.00$ 0.1 0.5 1 2 10	Residual heterogeneity: $I^2$	= 0%, p =	= 1.00			0.1 0.51 2 10				

Table 3 The results of subgroup analyses based on the surgical procedure and scope of gastrectomy

Outcomes	Scope of gastrecto	my		Surgical procedure	of gastrectomy	
	Radical gastrectomy	Distal Gastrectomy	Mix	Laparoscopic surgery	Open surgery	Mix
Lung infection	RR = 0.51,	RR = 0.35,	RR = 0.62,	RR = 0.72,	RR = 0.54,	RR = 0.54,
	95%CI[0.18; 1.40]	95%CI[0.04; 3.22]	95%CI[0.33; 1.15]	95%CI[0.19; 2.81]	95%CI[0.29; 1.01]	95%CI[0.15; 1.95]
Urinary tract infection	RR = 0.33,	RR = 0.98,	RR = 0.58,	RR = 2.14,	RR = 0.5,	RR = 0.60,
	95%[0.01; 8.02]	95%CI[0.14; 6.63]	95%CI[0.29; 1.19]	95%CI[0.20; 23.49]	95%CI[0.21; 1.21]	95%CI[0.20; 1.80]
Surgical site infection	RR = 0.51,	RR = 0.95,	RR = 0.94,	RR = 0.84,	RR = 0.77,	RR = 0.97,
	95%CI[0.10; 2.74]	95%CI[0.06; 14.22]	95%CI[0.45; 1.96]	95%CI[0.36; 1.95]	95%CI[0.18; 3.37]	95%CI[0.25; 3.75]
Postoperative anastomotic	RR = 0.34,	RR = 1.05,	RR = 1.21,	RR = 2.56,	RR = 1.15,	RR = 0.97,
leakage	95%CI[0.04; 3.25]	95%CI[0.07; 16.17]	95%CI[0.53; 2.74]	95%CI[0.39; 16.93]	95%CI[0.42; 3.10]	95%CI[0.23; 4.18]
Postoperative ileus	RR = 0.34,	RR = 1.05,	RR = 1.95,	RR = 0.69,	RR = 2.13,	RR = 1.00,
	95%CI[0.04; 3.25]	95%CI[0.07; 16.17]	95%CI[0.95; 4.02]	95%CI[0.12; 4.01]	95%CI[0.95; 4.81]	95%CI[0.23; 4.29]
Postoperative length of stay	MD = -1.79,	MD = -1.64,	MD = -1.88,	MD = -1.95,	MD = -1.83,	MD-1.36,
	95%CI[-2.59;	95%CI[-2.60;	95%CI[-2.63;-	95%CI[-2.99;	95%CI[-3.01;	95%CI[–1.70;
	-0.99]	-0.33]	1.12]	-0.91]	-0.66]	–1.03]
Flatus	MD = -0.75, 95%CI[-1.09; - 0.41]	MD = -0.45, 95%CI[- 0.62; - 0.28]	MD = -0.83, 95%CI[-1.22; -0.45]	MD = -0.81, 95%CI[- 2.04; 0.43]	MD = -0.68, 95%CI[- 1.08; - 0.27]	MD = -0.59, 95%CI[- 0.83; - 0.35]
Defecation	MD = -1.63, 95%CI[- 2.79; - 0.47]	Not applicable	MD = -0.54, 95%CI[- 0.86; - 0.22],	MD = -1.36, 95%CI[- 3.05; 0.34]	MD = -1.05, 95%CI[- 1.45; - 0.65]	MD = -0.65, 95%CI[- 1.28; - 0.02]
Readmission rates	RR = 1.02,	RR = 3.00,	RR = 1.99,	RR = 1.13,	RR = 2.64,	RR = 0.95,
	95%CI[0.02; 50.41]	95%CI[0.13; 69.79]	95%CI[1.04; 3.82]	95%CI[0.32; 4.08]	95%CI[1.20; 5.81]	95%Ci[0.06; 14.82]

Study	Experime Events	ental Total	Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
esophagectomy Zhang 2018 Fixed effect model Random effects model Heterogeneity: not applical	0 ble	57 57	1	57 - 57 -		0.33 0.33 0.33	[0.01; 8.01] [0.01; 8.01] [0.01; 8.01]	6.3% 6.3% 	4.2%  4.2%
gastrectomy Wang 2010 Chen(OS) 2012 Kim 2012 Feng 2013 Bu (45–74y) 2015 Bu (75–89y) 2015 Liu(LS) 2016 Liu(OS) 2016 Wu 2017 Fixed effect model Random effects model Heterogeneity: $J^2 = 0\%$ , $\tau^2$	0 0 1 0 2 3 1 2 0	45 21 22 59 64 64 21 21 34 <b>351</b>	1 1 0 1 4 6 2 3 0	47 20 22 59 64 64 21 21 41 359		0.35 0.32 - 3.00 0.33 0.56 0.54 0.60 0.71 - 1.20 0.60 0.60	[0.01; 8.32] [0.01; 7.36] [0.13; 69.79] [0.01; 8.02] [0.12; 2.51] [0.15; 1.88] [0.09; 4.15] [0.16; 3.23] [0.02; 59.06] [0.31; 1.16] [0.31; 1.17]	6.1% 6.4% 2.1% 6.3% 18.8% 27.1% 10.4% 14.6% 1.9% 93.7%	4.2% 4.3% 4.2% 18.7% 27.1% 11.4% 18.7% 2.8%  95.8%
<b>Fixed effect model</b> <b>Random effects model</b> Heterogeneity: $I^2 = 0\%$ , $\tau^2$ Residual heterogeneity: $I^2$ <b>Fig. 3</b> Forest plot evaluating	= 0, <i>p</i> = 0. = 0%, <i>p</i> = postoperat	<b>408</b> 99 0.99 ive uri	nary tract i	<b>416</b> infectior	0.1 0.51 2 10 between ERAS and conventional	<b>0.59</b> <b>0.59</b> care	[0.31; 1.11] [0.31; 1.13]	100.0% 	 100.0%

analyses of SSI based on the surgical procedure and scope of gastrectomy.

# Postoperative anastomotic leakage

Fourteen RCTs including 1414 patients reported postoperative anastomotic leakage. Pooling the results suggested that ERAS protocols did not increase the incidence of postoperative anastomotic leakage compared to conventional care (Fig. 5, RR = 0.80, 95%CI: 0.44 to 1.45). The test of heterogeneity ( $I^2 = 0\%$ ) indicated that there was little heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated that the incidence of anastomotic leakage after surgery was not increased by ERAS protocols (Fig. 5, RR = 1.27 95%CI: 0.60 to 2.66,  $I^2 = 0\%$ ). Among RCTs performed in the area of esophagectomies, postoperative anastomotic leakage (Fig. 5, RR = 0.31, 95%CI: 0.09 to 1.01,  $I^2 = 2\%$ ) was not increased by ERAS protocols. However, there were no statistical differences in all subgroup analyses of postoperative anastomotic leakage based on the surgical procedure and scope of gastrectomy in Table 3.

# Postoperative ileus

Thirteen RCTs (1313 patients) reported postoperative ileus. Pooling the results suggested that ERAS protocols did not increase the incidence of postoperative ileus compared to conventional care (Fig. 6, RR = 1.43, 95%CI: 0.78 to 2.65). The test of heterogeneity ( $I^2 = 0\%$ ) indicated that there was little heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated that the incidence of ileus after surgery was not increased by ERAS protocols (Fig. 6, RR = 1.56, 95%CI: 0.82 to 2.97,  $I^2 = 0\%$ ). In the area of esophagectomies, postoperative anastomotic leakage (Fig. 6, RR = 1.56, 95%CI: 0.82 to 2.97,  $I^2 = 0\%$ ) was not increased by ERAS protocols. However, the results that there were no statistical differences were found in all subgroup analyses of postoperative anastomotic leakage based on the surgical procedure and scope of gastrectomy (Table 3).

# Secondary outcomes

### Postoperative length of stay.

Eighteen RCTs (1716 patients) reported PLOS. Pooling the results suggested that ERAS protocols significantly decreased the postoperative length of stay compared to conventional care (Fig. 7, MD = -2.53, 95%CI: -3.42 to -1.65). The test of heterogeneity (I<sup>2</sup> = 97%) indicated that there was a high degree of heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated that PLOS was significantly reduced by ERAS protocols (Fig. 7, MD = -1.77, 95%CI = -2.29

Study	Experim Events	ental Total	Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
esophagectomy Zhao 2014 Chen 2016 Zhang 2017 Zhang 2018 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$ , $\tau^2$	1 2 0 1 = 0, p = 0.	34 128 47 57 266	1 2 2 2	34 132 47 57 270		1.00 1.03 0.20 0.60 0.67 0.72	[0.11; 9.15] [0.18; 5.85] [0.01; 4.06] [0.08; 4.39] [0.24; 1.86] [0.25; 2.06]	5.1% 8.4% 8.5% 8.5% 30.5%	6.4% 10.4% 3.5% 7.9%  28.2%
gastrectomy Wang 2010 Chen(OS) 2012 Feng 2013 Bu (45-74y) 2015 Bu (75-89y) 2015 Abdikarim 2015 Liu(LS) 2016 Liu(OS) 2016 Tanaka 2017 Xia 2017 Wu 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\%$ , $\tau^2$	$ \begin{array}{c} 2 \\ 1 \\ 2 \\ 4 \\ 0 \\ 1 \\ 0 \\ 1 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0$	45 21 59 64 30 21 21 73 73 34 505	1 3 5 2 1 0 0 1 1 0	47 20 60 64 64 31 21 21 69 76 41 514		1.74 0.95 0.44 0.45 1.80 0.34 1.00 3.00 0.32 1.04 1.20 <b>0.86</b> <b>0.87</b>	[0.24; 12.64] [0.11; 8.44] [0.07; 2.85] [0.11; 1.95] [0.40; 8.12] [0.01; 8.13] [0.02; 48.14] [0.13; 69.61] [0.13; 69.61] [0.11; 9.78] [0.02; 59.06] [0.46; 1.61] [0.45; 1.69]	5.0% 5.2% 11.8% 18.7% 8.5% 5.0% 1.7% 5.2% 5.0% 1.5% 69.5%	8.0% 6.6% 8.9% 14.8% 13.8% 3.1% 2.1% 3.2% 3.1% 6.2% 2.1%  71.8%
<b>Fixed effect model</b> <b>Random effects model</b> Heterogeneity: $l^2 = 0\%$ , $\tau^2$ Residual heterogeneity: $l^2$ <b>Fig. 4</b> Forest plot evaluation	= 0, <i>p</i> = 0. = 0%, <i>p</i> =	771 98 0.97	raical site i	784 [ 0.0	D1 0.1 1 10 19	0.80 0.83 1 00	[0.47; 1.37] [0.47; 1.45]	100.0% 	 100.0%

to -1.24,  $I^2 = 85.8\%$ ). Among RCTs performed in the area of esophagectomies, PLOS was significantly reduced by ERAS protocols (Fig. 7, MD = -5.12, 95%CI: -5.40 to -4.83,  $I^2 = 34\%$ ). Based on the surgical procedure and scope of gastrectomy, all subgroup analyses in PLOS, including radical gastrectomy (MD = -1.79, 95%CI: -2.59 to -0.99), distal gastrectomy (MD = -1.64, 95%CI: -2.60 to -0.33), laparoscopic surgery (MD = -1.83, 95%CI: -2.99 to -0.91), and open surgery (MD = -1.83, 95%CI: -3.01 to -0.66), showed statistical differences by ERAS protocols in Table 3.

### The duration of intestinal function recovery

Thirteen RCTs (1072 patients) reported the time until the first postoperative flatus. Pooling the results suggested that ERAS protocols significantly decreased the time until the first postoperative flatus compared to conventional care (Fig. 8, MD = -0.65, 95% CI: -0.85 to -0.45). The test of heterogeneity (I<sup>2</sup> = 82%) indicated that there was significant heterogeneity among these trials.

Five RCTs (539 patients) reported the time until the first postoperative defecation. Pooling the results suggested that ERAS protocols significantly decreased the time until the first postoperative defecation compared to

conventional care (Fig. 9, MD = -1.10, 95% CI: -1.74 to -0.47). The test of heterogeneity (I<sup>2</sup> = 87%) indicated that there was significant heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated that ERAS was associated with a significant reduction in the time until the first postoperative flatus (Fig. 8, MD = -0.68, 95%CI: -0.85 to -0.45,  $I^2 = 74\%$ ) and until the first postoperative defecation (Fig. 9, MD = -1.11, 95%CI: -1.85 to -0.36, I<sup>2</sup> = 90%). However, for the esophagectomies, ERAS protocols significantly decreased the time until the first postoperative defecation (Fig. 9, MD = -1.09, 95%CI: -1.88 to -0.30,  $I^2$  = Not applicable), but it wasn't decreased the time the first postoperative flatus (Fig. 8, MD = -0.62, 95%CI: -1.32 to 0.09, I<sup>2</sup> = 84%). Based on the surgical procedure and scope of gastrectomy, the subgroup analyses of first postoperative flatus, including radical gastrectomy (MD = -0.75, 95%CI: -1.09 to -0.41), distal gastrectomy (MD = -0.45, 95%CI: -0.62 to -0.28), and open surgery (MD = -0.599, 95%CI: -1.08 to -0.27), showed statistical differences by ERAS protocols, but laparoscopic surgery (MD = -0.81, 95%CI: -2.04 to 0.43) wasn't statistical differences in Table 3. Subgroup

Study	Experim Events	ental Total	Co Events	ontrol Total		Ri	sk Ratio	þ		RR	9	5%-CI	Weight (fixed)	Weight (random)
esophagectomy Zhao 2014 Chen 2016 Li 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 2\%$ , $\tau^2$	0 2 0 = 0.0324,	34 128 55 <b>217</b> p = 0.3	1 3 6	34 132 55 221				_		0.33 0.74 0.08 0.31 0.41	[0.01; [0.15; [0.00; [0.09; [0.11;	7.90] 3.67] 1.33] 1.01] 1.49]	6.4% 14.7% 27.8% 48.9%	4.5% 17.4% 5.5%  27.4%
gastrectomy Wang 2010 Chen(OS) 2012 Chen(LS) 2012 Feng 2013 Bu (45-74y) 2015 Bu (75-89y) 2015 Abdikarim 2015 Tanaka 2017 Xia 2017 Wu 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\% t^2$	$ \begin{array}{c} 0 \\ 0 \\ 0 \\ 1 \\ 5 \\ 0 \\ 2 \\ 1 \\ 1 \end{array} $	45 21 19 59 64 64 30 73 73 34 482	0 0 0 3 2 0 2 0 0 0	47 20 22 60 64 64 31 69 76 41 494	-					1.04 0.95 1.15 1.02 0.43 2.20 1.03 0.95 3.12 3.61 1.27 1.25	[0.02; [0.02; [0.02; [0.02; [0.07; [0.51; [0.02; [0.17; [0.13; [0.15; [0.60; [0.57;	51.51] 45.85] 55.47] 50.41] 2.81] 9.42] 50.42] 5.29] 75.43] 85.79] 2.66] 2.75]	2.1% 2.2% 2.1% 14.9% 10.7% 2.1% 11.0% 2.1% 1.9% 51.1%	2.9% 3.0% 2.9% 12.7% 21.2% 3.0% 15.1% 4.4% 4.5%
Fixed effect model Random effects model Heterogeneity: $I^2 = 0\%$ , $\tau^2$ Residual heterogeneity: $I^2$ Fig. 5 Forest plot evaluating	= 0, <i>p</i> = 0. = 0%, <i>p</i> =	<b>699</b> 87 0.94 tive and	astomotic	<b>715</b> leakag	<b>0.01</b> e betwe	I 0.1 een ERAS	1	1 10 iventic	100 Donal car	0.80 0.92	[0.44; [0.47;	1.45] 1.80]	100.0% 	 100.0%

analyses of first postoperative defecation, including radical gastrectomy (MD = -1.63, 95%CI: -2.79 to -0.47) and open surgery (MD = -1.05, 95%CI: -1.45 to -0.65), showed statistical differences by ERAS protocols, but laparoscopic surgery (MD = -1.36, 95%CI: -3.05 to 0.34) wasn't statistical differences in Table 3.

#### **Readmission rates**

Eleven RCTs (1211 patients) reported postoperative readmission rates. Pooling the results suggested that ERAS protocols didnot increase postoperative readmission rates compared to conventional care (Fig. 10, RR = 1.29, 95%CI: 0.79 to 2.12). The test of heterogeneity ( $I^2 = 4\%$ ) indicated that there was little heterogeneity among these trials.

Among RCTs performed in the area of gastric surgery, analysis indicated readmission was significantly increased by ERAS protocols (Fig. 10, RR = 1.99, 95%CI: 1.06 to 3.73,  $I^2 = 0\%$ ). Among RCTs performed in the area of esophagectomies, readmission rates were not increased by ERAS protocols (Fig. 10, RR = 0.63, 95%CI: 0.14 to 2.80,  $I^2 = 44\%$ ). However, the results that there were no statistical differences were found in all subgroup analyses of readmission rates based on the surgical procedure and scope of gastrectomy (Table 3).

#### **Publication bias**

There was no evidence of asymmetry in these Doi plots (LFK index < |2|) of the risk of postoperative LI, UTI, SSI and postoperative anastomotic leakage. However, the obvious publication bias was observed in postoperative ileus.

#### Discussion

This is a meta-analysis of ERAS protocols in all upper gastrointestinal surgeries. It is also one of the largest studies of upper gastrointestinal RCTs to date. The analysis that we performed indicates that ERAS protocols significantly decreased the incidence of postoperative LI compared to conventional care. ERAS protocols did not increase the incidence of postoperative UTI, SSI, ileus and anastomotic leakage in patients who underwent upper gastrointestinal surgery. Nonetheless, ERAS protocols accelerated patients' postoperative recovery times.

In all invasive surgeries, the postoperative infection (POI) is a common cause of harm to the patients during the recovery period. A systematic review and metaanalysis [35] indicated that ERAS protocols significantly decreased POI. Most of the ERAS protocol items were included in the studies. Daily smokers have an increased risk of lung infection [36] and postoperative surgical site

Study	Experime Events	ental Total	Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
esophagectomy Zhao 2014 Chen 2016 Fixed effect model Random effects mode Heterogeneity: / <sup>2</sup> = 0%, τ		34 128 162	1 0	34 132 166		0.33 1.03 0.51 0.52	[0.01; 7.90] [0.02; 51.58] [0.05; 5.45] [0.04; 6.11]	9.1% 3.0% 12.1%	4.4% 2.9%  7.3%
gastrectomy Wang 2010 Chen(LS) 2012 Chen(OS) 2012 Feng 2013 Abdikarim 2015 Bu(45-74y) 2015 Bu(75-89y) 2015 Liu(LS) 2016 Liu(OS) 2016 Xia 2017 Tanaka 2017 Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$ , $\tau^2$	$ \begin{array}{c} 0 \\ 0 \\ 0 \\ 1 \\ 5 \\ 10 \\ 1 \\ 0 \\ 0 \\ 0 \\ \end{array} $	45 19 21 59 30 64 64 21 73 73 73 <b>490</b>	0 0 1 1 2 3 0 0 1 1	47 22 20 60 31 64 64 21 21 76 69 495		1.04 1.15 0.95 0.34 1.03 2.20 3.00 3.00 1.00 0.35 0.32 1.56 1.61	[0.02; 51.51] [0.02; 55.47] [0.02; 45.85] [0.01; 8.15] [0.11; 9.39] [0.51; 9.42] [0.94; 9.56] [0.13; 69.61] [0.02; 48.14] [0.01; 8.38] [0.01; 7.61] [0.82; 2.97] [0.80; 3.22]	3.0% 2.8% 3.1% 9.0% 15.2% 21.3% 3.0% 3.0% 8.9% 9.4% 87.9%	2.9% 3.0% 3.0% 4.4% 9.1% 21.0% 33.1% 4.5% 3.0% 4.4% 4.4%  92.7%
Fixed effect model Random effects mode Heterogeneity: $I^2 = 0\%$ , $\tau^2$ Residual heterogeneity: $I^2$ Fig. 6 Forest plot evaluating	$p^{2} = 0, p = 0.$ $p^{2} = 0\%, p = 0.$	<b>652</b> 94 0.94 tive ile	us betwee	<b>661</b> n ERAS	0.1 0.51 2 10 and conventional care	1.43 1.48	[0.78; 2.65] [0.76; 2.89]	100.0% 	 100.0%

infection [37]. Preoperative optimization, smoking cessation and refraining from drinking, implementing epidural analgesia [38], fluid management [39], and early mobilization [40] are all steps that can be taken to reduce the incidence of lung infections. ERAS protocols have created a good environment for avoiding postoperative UTI, such as using antimicrobial prophylaxis, maintaining fluid balance [39], and avoiding urinary catheters or removing them early [41]. Non-opioid analgesics can be used to prevent urinary retention. A metaanalysis indicated [42] that the epidural analgesia provided significant improvement in postoperative pain control compared to opioid analgesia. Moreover, using epidurals can decrease insulin resistance. Antimicrobial prophylaxis can be used prior to making a skin incision to prevent SSI [43]. Intake of carbohydrates up to 2 h before anaesthesia does not increase rates of delayed gastric emptying and is recommended prior to surgery [44]. Other practices [6, 34] in ERAS protocols include the use of preoperative carbohydrates, procedures to avoid hypothermia, complete avoidance of the use of nasogastric tubes, and early oral feeding and mobilization.

Traditionally, oral intake was delayed after gastrointestinal surgery to protect anastomoses and prevent postoperative ileus. Early oral feeding in ERAS protocols may increase the risk of vomiting [45]. However, three studies have shown that early oral feeding is not only safe, but it is beneficial to the process of functional recovery [46–48]. A decreased of postoperative gastro-intestinal paralysis and ileus was found for epidural anaesthetic compared with epidural opioids in one Cochrane review [49]. Most of the studies we included used early oral feeding, we included more RCTs demonstrating that the use of ERAS does not increase rates of postoperative ileus.

More importantly, this meta-analysis showed that ERAS maybe increased postoperative ileus and readmission rates in patients who underwent upper gastrointestinal surgery, but these failed to reach significance (P > 0.10). In the gastrectomy analysis of postoperative ileus rates, we found that the incidence of postoperative ileus in two studies [21, 23] were significantly higher than other studies. The age of the included population in both studies was over 65 years old, it is also the highest in all studies. We exclude these two studies, we found no difference in the incidence of postoperative ileus compared with conventional care. Therefore, according to the available evidence indicates that we should carefully consider whether ERAS should be used in elderly patients undergoing gastric cancer surgery.

Study	Experimental Total Mean SD	Control Total Mean SD	Mean Difference	Weight MD 95%-CI (fixed)	Weight (random)
esophagectomy Zhao 2014 Chen 2016 Li 2017 Zhang 2017 Fixed effect model Random effects model Heterogeneity: $J^2 = 34\%$ , $\tau$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	34 12.52 1.47 132 12.56 1.92 55 13.72 1.63 47 11.52 4.57 268	* * * *	-5.37       [-6.01; -4.73]       5.5%         -4.94       [-5.35; -4.53]       13.8%         -5.41       [-5.95; -4.87]       7.7%         -4.04       [-5.50; -2.58]       1.1%         -5.12       [-5.40; -4.83]       28.1%         -5.13       [-5.51; -4.74]	5.8% 5.9% 5.2%  22.8%
gastrectomy Wang 2010 Kim 2012 Chen (LS) 2012 Chen (OS) 2012 Feng 2013 Bu (45-74y) 2015 Bu (75-89y) 2015 Abdikarim 2015 Liu (LS) 2016 Liu (OS) 2016 Fujikuni 2016 Tanaka 2017 Xia 2017 Wu 2017 Fixed effect model Random effects model Heterogeneity: $J^2 = 86\%$ , c	45 6.35 0.76 22 5.36 1.46 19 7.15 1.04 21 7.70 1.15 59 5.68 1.22 64 6.50 1.70 64 10.00 2.30 30 6.80 1.10 21 6.30 1.50 21 7.80 1.80 40 10.22 2.89 73 9.00 1.50 73 6.38 2.04 34 14.06 5.05 586 $2^2 = 0.7635, p < 0.01$	477.650.76227.951.98227.701.15209.101.62607.102.136410.302.006410.802.50317.701.10219.602.002110.502.104011.003.306910.181.87768.622.874117.179.27598		$\begin{array}{ccccc} -1.30 & [-1.61; -0.99] & 23.6\% \\ -2.59 & [-3.62; -1.56] & 2.2\% \\ -0.55 & [-1.22; 0.12] & 5.1\% \\ -1.40 & [-2.26; -0.54] & 3.1\% \\ -1.42 & [-2.04; -0.80] & 5.9\% \\ -3.80 & [-4.44; -3.16] & 5.5\% \\ -0.80 & [-1.63; 0.03] & 3.3\% \\ -0.90 & [-1.45; -0.35] & 7.5\% \\ -3.30 & [-4.37; -2.23] & 2.0\% \\ -2.70 & [-3.88; -1.52] & 1.6\% \\ -0.78 & [-2.14; 0.58] & 1.2\% \\ -1.18 & [-1.74; -0.62] & 7.3\% \\ -2.24 & [-3.04; -1.44] & 3.6\% \\ -3.11 & [-6.42; 0.20] & 0.2\% \\ -1.54 & [-1.72; -1.37] & 71.9\% \\ -1.77 & [-2.29; -1.24] & \end{array}$	6.0% 5.6% 5.8% 5.7% 5.8% 5.9% 5.5% 5.4% 5.3% 5.9% 5.7% 3.3%  77.2%
Fixed effect model Random effects model Heterogeneity: $l^2 = 97\%$ , $\tau$ Residual heterogeneity: $l^2$ Fig. 7 Forest plot evaluatii	<b>850</b> $^{2} = 3.4184, p < 0.01$ = 83%, p < 0.01 ng postoperative PLC	<b>866</b> DS between ERAS ar	-6 -4 -2 0 2 4 and conventional care	-2.55 [-2.70; -2.40] 100.0% -2.53 [-3.42; -1.65]	 100.0%

We included more studies and found that readmission rates did not increase for all Upper Gastrointestinal Surgeries as a result of ERAS. However, a meta-analysis [10] revealed that ERAS protocols increased the postoperative readmission rates for gastric surgery patients. This is a completely different result from previous metaanalyses [50, 51]. Our subgroup analysis showed that the readmission rates of gastric surgery patients also increased. Excluding the elderly patients in Bu's study [21] indicated that there was no increase in readmission rates between ERAS and conventional care groups. A RCT [23] showed ERAS combined with laparoscopic surgery can accelerate postoperative recovery time, reduce postoperative stress reaction for elderly GC patients. We tried to explore the benefits of laparoscopy combined with ERAS in the elderly, but the available RCTs too few. RCTs with large studies are needed to more precisely evaluate ERAS in elderly patients. PLOS was shortened 2.68 days and time until the first flatus was shortened by 0.71 days by using ERAS protocols compared to conventional care. These present results are consistent with a previous analysis that was reported by Siotos [9]. Our research also confirms that other than the postoperative length of stay and intestinal function recovery, ERAS protocols does not have a large impact on the scope and surgical procedure of gastrectomy. Compared with laparoscopic surgery, ERAS protocols is more profitable in open surgery. Of course, it is possible that the characteristics of laparoscopic surgery with less trauma and faster recovery make it difficult for ERAS protocols to give full play to its own efficacy. Finally, the accuracy of this result may also be caused by the small sample after being divided by the subgroup ananlysis, which needs to be verified by a larger sample study.

This study provides more evidence to support the published guidelines [6, 34]. A meta-analysis [52] of observational studies for ERAS protocols used in esophagectomies. Six retrospective studies have assessed ERAS protocols for patients who have undergone an esophagectomy. We assessed ERAS for esophagectomies across five RCTs. This meta-analysis indicated that ERAS can shorten PLOS without increasing morbidity and postoperative complications for esophagectomies. Consensus guidelines for enhanced recovery after gastrectomy [6] indicated the quality of current evidence varies substantially and further research need to improve

Study	Ex <sub>l</sub> Total	perimo Mean	ental SD	Total	Co Mean	ntrol SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
esophagectomy Zhao 2014 Li 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 84\%$ , $\tau$	<b>34</b> <b>55</b> <b>89</b> <sup>2</sup> = 0.224	1.91 0.49 46, <i>p</i> =	1.13 0.07	34 55 89	2.95 0.80	1.25 0.10	•	-1.04 -0.31 -0.31 -0.62	[-1.61; -0.47] [-0.34; -0.28] [-0.34; -0.28] [-1.32; 0.09]	0.3% 92.1% 92.4%	5.9% 11.2%  17.1%
gastrectomy Wang 2010 Chen(LS) 2012 Chen(OS) 2012 Kim 2012 Feng 2013 Bu (45-74y) 2015 Bu (75-89y) 2015 Liu (LS) 2016 Tanaka 2017 Wu 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 74\%$ , $\tau$	$45 \\ 19 \\ 21 \\ 22 \\ 59 \\ 64 \\ 64 \\ 21 \\ 21 \\ 73 \\ 34 \\ 443 \\ 2^2 = 0.10^4$	3.00 2.36 2.72 2.63 2.54 3.20 2.50 1.65 3.12	1.50 0.42 0.34 0.78 1.02 1.00 1.00 1.20 1.10 0.76 0.88	47 22 20 22 60 64 64 21 21 69 41 451	4.35 2.76 3.28 2.81 3.29 3.60 3.80 3.10 3.60 2.00 4.56	0.75 0.58 0.40 0.64 1.00 1.20 1.00 0.90 1.50 1.16		-1.35 -0.40 -0.56 -0.18 -0.75 -0.40 -0.30 -1.10 -1.10 -0.35 -1.44 -0.60 -0.68	$\begin{matrix} [-1.84; -0.86] \\ [-0.71; -0.09] \\ [-0.79; -0.33] \\ [-0.60; 0.24] \\ [-1.09; -0.41] \\ [-0.75; -0.05] \\ [-0.68; 0.08] \\ [-1.77; -0.43] \\ [-1.77; -0.43] \\ [-0.74; 0.04] \\ [-0.74; 0.04] \\ [-1.90; -0.98] \\ [-0.72; -0.49] \\ [-0.91; -0.45] \end{matrix}$	0.4% 1.0% 1.8% 0.5% 0.8% 0.2% 0.3% 0.3% 0.6% 0.4% 7.6%	6.7% 8.9% 9.8% 7.5% 8.5% 8.4% 7.9% 5.0% 5.5% 7.8% 7.0%  82.9%
Fixed effect model Random effects model Heterogeneity: $I^2 = 82\%$ , $\tau^2$ Residual heterogeneity: $I^2$ Fig. 8 Forest plot evaluatin	<b>532</b> <sup>2</sup> = 0.092 = 75%, j ng the d	28, p < p < 0.0 lurtion	: <b>0.01</b> 0 <b>1</b> of the	<b>540</b> e first fla	atus be	tween	-1.5 -1 -0.5 0 0.5 1 1.5 ERAS and conventional care	-0.33 -0.65	[-0.37; -0.30] [-0.85; -0.45]	100.0% 	 100.0%

the strength of evidence. The current consensus on the use of ERAS in esophageal surgery [34] does not indicate the benefits of ERAS implementation due to the lack of available research. Our research provides strength of evidence regarding RCTs to support the publication of consensus guidelines on the use of ERAS in gastrectomy and esophagectomy.

Without adoubt, there are several limitations in this study. First, there have been too few RCTs conducted in the area of esophagectomies. Second, there was heterogeneity for PLOS and the time until the first postoperative flatus and defecation. This compelling heterogeneity may be attributable to clinical factors, including the technical skill level of the hospital and surgeon, surgical

Study	Ex Total	perim Mean	ental SD	Total	Co Mean	ntrol SD	Mean Difference	MD	95%-CI	Weight (fixed)	Weight (random)
esophagectomy Zhao 2014 Fixed effect model Random effects model Heterogeneity: not applicat	34 34	3.75	1.54	34 34	4.84	1.76		-1.09 -1.09 -1.09	[-1.88; -0.30] [-1.88; -0.30] [-1.88; -0.30]	7.5% 7.5% 	17.2%  17.2%
gastrectomy Abdikarim 2015 Feng 2013 Xia 2017 Tanaka 2017 Fixed effect model Random effects model Heterogeneity: $J^2 = 90\%$ , $\tau$	$30597373235^2 = 0.52$	3.10 2.83 2.97 3.35	0.70 1.06 1.23 2.27	31 60 76 69 236	3.60 3.88 5.20 4.00	0.80 1.16 1.81 1.51		-0.50 -1.05 -2.23 -0.65 -1.05 -1.11	[-0.88; -0.12] [-1.45; -0.65] [-2.73; -1.73] [-1.28; -0.02] [-1.27; -0.82] [-1.85; -0.36]	32.7% 29.2% 18.9% 11.7% 92.5%	21.7% 21.5% 20.5% 19.0%  82.8%
Fixed effect model Random effects model Heterogeneity: $l^2 = 87\%$ , $\tau$ Residual heterogeneity: $l^2$	<b>269</b> $^{2} = 0.44$ = 90%,	25, p < p < 0.0	: 0.01 )1	<b>270</b>	ofocati	an hot	-2 -1 0 1 2	-1.05 -1.10	[-1.27; -0.83] [-1.74; -0.47]	100.0% 	 100.0%

Study	Experim Events	ental Total	Co Events	ontrol Total	Risk Ratio	RR	95%-CI	Weight (fixed)	Weight (random)
esophagectomy Zhao 2014 Chen 2016 Zhang 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 44\%$ , t	1 3 1 . <sup>2</sup> = 0.7698	34 128 47 <b>209</b>	0 3 8 0.17	34 132 47 213		- 3.00 1.03 0.18 0.53 0.63	[0.13; 71.11] [0.24; 4.45] [0.03; 0.95] [0.21; 1.33] [0.14; 2.80]	1.9% 13.2% 32.5% 47.6%	3.2% 14.4% 11.0%  28.6%
gastrectomy Abdikarim 2015 Bu(45-74y) 2015 Bu(75-89) 2015 Feng 2013 Kim 2012 Tanaka 2017 Wang 2010 Wu 2017 Fixed effect model Random effects model Heterogeneity: $l^2 = 0\% \tau^2$	$ \begin{array}{c} 0 \\ 6 \\ 12 \\ 0 \\ 1 \\ 1 \\ 2 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0$	30 64 69 22 73 45 34 <b>391</b>	0 2 3 0 0 1 1 3	31 64 60 22 69 47 41 398		1.03 2.60 3.57 1.02 - 3.00 0.95 1.04 0.86 1.99 1.92	[0.02; 50.42] [0.63; 10.73] [1.15; 11.10] [0.02; 50.41] [0.13; 69.79] [0.10; 8.88] [0.11; 9.67] [0.18; 4.08] [1.06; 3.73] [1.00; 3.70]	1.9% 9.6% 13.4% 1.9% 5.9% 5.6% 12.2% 52.4%	2.2% 15.3% 23.0% 2.1% 3.3% 6.4% 6.4% 12.8%  71.4%
<b>Fixed effect model</b> <b>Random effects model</b> Heterogeneity: $l^2 = 4\%$ , $\tau^2$ Residual heterogeneity: $l^2$ <b>Fig. 10</b> Forest plot evaluatir	= 0.0375, = 0%, p =	600 p = 0.4 0.65 ence c	<b>41</b> of readmiss	<b>611</b> ion betw	0.1 0.51 2 10 veen ERAS and conventional care	1.29 1.36	[0.79; 2.12] [0.76; 2.41]	100.0% 	 100.0%

procedures, and conflicting evaluation of the outcomes. Furthermore, we found that the different types and purposes of surgery, including gastric resection for cancer and sleeve gastrectomy for obesity, were also centralized pooled, which may increase some clinical heterogeneity. In addition, there was not uniform implementation of ERAS recommendations. For example, there were different standards for liquid management documented. Despite attempting to find these types of variations through subgroup analysis, we were unable to detect the source of the heterogeneity. The postoperative ileus rates showed major asymmetry in the Doi plots as evidence of publication bias, which may affect the pooled results. Finally, since many of these studies do not use appropriate randomisation procedures and do not report their methods for from chinese-language studies, there may be potential language bias in this study based on select only English-language studies.

# Conclusions

This study found that ERAS programmes are associated with a significant reduction in postoperative LI, Meanwhile ERAS protocols accelerate patients' postoperative recovery times included the first postoperative flatus, defecation and PLOS, regardless of the scope and surgical procedure of gastrectomy. We also found that perform ERAS may increase the risk of postoperative ileus or readmission rate. Although, to be truly effective interventions, as the ultimate quality improvement practice, is the key to measuring the success of ERAS, our research provides some reference evidence to advance ERAS into clinical practice.

#### Supplementary information

Supplementary information accompanies this paper at https://doi.org/10. 1186/s12893-019-0669-3.

Additional file 1. Search strategy.
Additional file 2. Reasons for excluding studies by reading full-text.
Additional file 3. Assessment of risk of bias.

#### Abbreviations

CI: Confidence intervals; ERAS: Enhanced recovery after surgery; LI: Lung infection; MD: Mean difference; PLOS: Postoperative length of stay; POI: Postoperative infection; RCT: Randomized controlled trial; REM: Random effects model; SSI: Surgical site infection; UTI: Urinary tract infection

#### Acknowledgements

None.

#### Authors' contributions

YBL and CZ contributed to the study conception and design, the acquisition of data, and the drafting of the manuscript. ZDH, HYG, JZ, JL, QFD and XFS contributed to the analysis and interpretation of the quantitative data, and the drafting of the manuscript. ZDH and HYG contributed to the development of critical revising of the final draft. YBL and CZ contributed to the analysis and interpretation of the descriptive and the revising the final draft. All authors have read and approved the manuscript.

#### Funding

This study was supported by the Guiding Project of Shiyan City (No.18Y29). The funders had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

#### Availability of data and materials

Not applicable.

**Ethics approval and consent to participate** Not applicable.

#### Consent for publication

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

#### Author details

<sup>1</sup>Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, No.32, South Renmin Road, Shiyan 442000, China. <sup>2</sup>Department of Orthopedic, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430000, China. <sup>3</sup>Trade Union, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China. <sup>4</sup>Department of General Surgery, Taihe Hospital, Hubei University of Medicine, No.32, South Renmin Road, Shiyan 442000, China.

#### Received: 14 August 2019 Accepted: 19 December 2019 Published online: 03 January 2020

#### References

- Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth. 1997;78:606–17.
- Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152:292–8.
- Keil DS, Schiff LD, Carey ET, Moulder JK, Goetzinger AM, Patidar SM, et al. Predictors of Admission After the Implementation of an Enhanced Recovery After Surgery Pathway for Minimally Invasive Gynecologic Surgery. Anesth Analg. 2019;129:776–3.
- Vukovic N, Dinic L. Enhanced Recovery After Surgery Protocols in Major Urologic Surgery. Front Med (Lausanne). 2018;5:93.
- 5. Segelman J, Nygren J. Best practice in major elective rectal/pelvic surgery: enhanced recovery after surgery (ERAS). Updat Surg. 2017;69:435–9.
- Mortensen K, Nilsson M, Slim K, Schafer M, Mariette C, Braga M, et al. Consensus guidelines for enhanced recovery after gastrectomy: enhanced recovery after surgery (ERAS(R)) society recommendations. Br J Surg. 2014; 101:1209–29.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7–30.
- Okuno K. Surgical treatment for digestive cancer. Current issues colon cancer. Dig Surg. 2007;24:108–14.
- Siotos C, Stergios K, Naska A, Frountzas M, Pergialiotis V, Perrea DN, et al. The impact of fast track protocols in upper gastrointestinal surgery: a metaanalysis of observational studies. Surgeon. 2018;16:183–92.
- Wang LH, Zhu RF, Gao C, Wang SL, Shen LZ. Application of enhanced recovery after gastric cancer surgery: an updated meta-analysis. World J Gastroenterol. 2018;24:1562–78.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
- Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16:195–203.
- Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785–805.
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

- 16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions; 2011.
- Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007;7:5.
- Wang D, Kong Y, Zhong B, Zhou X, Zhou Y. Fast-track surgery improves postoperative recovery in patients with gastric cancer: a randomized comparison with conventional postoperative care. J Gastrointest Surg. 2010;14:620–7.
- Chen Hu J, Xin Jiang L, Cai L, Tao Zheng H, Yuan Hu S, Bing Chen H, et al. Preliminary experience of fast-track surgery combined with laparoscopyassisted radical distal gastrectomy for gastric cancer. J Gastrointest Surg. 2012;16:1830–9.
- Feng F, Ji G, Li JP, Li XH, Shi H, Zhao ZW, et al. Fast-track surgery could improve postoperative recovery in radical total gastrectomy patients. World J Gastroenterol. 2013;19:3642–8.
- Bu J, Li N, Huang X, He S, Wen J, Wu X. Feasibility of fast-track surgery in elderly patients with gastric Cancer. J Gastrointest Surg. 2015;19:1391–8.
- 22. Abdikarim I, Cao XY, Li SZ, Zhao YQ, Taupyk Y, Wang Q. Enhanced recovery after surgery with laparoscopic radical gastrectomy for stomach carcinomas. World J Gastroenterol. 2015;21:13339–44.
- Liu G, Jian F, Wang X, Chen L. Fast-track surgery protocol in elderly patients undergoing laparoscopic radical gastrectomy for gastric cancer: a randomized controlled trial. Onco Targets Ther. 2016;9:3345–51.
- Fujikuni N, Tanabe K, Tokumoto N, Suzuki T, Hattori M, Misumi T, et al. Enhanced recovery program is safe and improves postoperative insulin resistance in gastrectomy. World J Gastrointest Surg. 2016;8:382–8.
- Tanaka R, Lee SW, Kawai M, Tashiro K, Kawashima S, Kagota S, et al. Protocol for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial. Gastric Cancer. 2017; 20:861–71.
- Xia M, Zhang L, Tang Z, Zzhao Y, Wang Q. Laparoscopic radical Gastrectomy for Resectable advanced gastric Cancer within enhanced recovery programs: a prospective randomized controlled trial. J Laparoendosc Adv Surg Tech A. 2017;27:959–64.
- Wu J, Sha H, Ren X, Hong X. Fast-track surgery could improve postoperative recovery in patients with laparoscopy D2 Gastrectomy. Int Surg. 2017;102: 151–6.
- Kim JW, Kim WS, Cheong JH, Hyung WJ, Choi SH, Noh SH. Safety and efficacy of fast-track surgery in laparoscopic distal gastrectomy for gastric cancer: a randomized clinical trial. World J Surg. 2012;36:2879–87.
- 29. Zhao G, Cao S, Cui J. Fast-track surgery improves postoperative clinical recovery and reduces postoperative insulin resistance after esophagectomy for esophageal cancer. Support Care Cancer. 2014;22:351–8.
- Chen L, Sun L, Lang Y, Wu J, Yao L, Ning J, et al. Fast-track surgery improves postoperative clinical recovery and cellular and humoral immunity after esophagectomy for esophageal cancer. BMC Cancer. 2016;16:449.
- Li W, Zheng B, Zhang S, Chen H, Zheng W, Chen C. Feasibility and outcomes of modified enhanced recovery after surgery for nursing management of aged patients undergoing esophagectomy. J Thorac Dis. 2017;9:5212–9.
- 32. Zhang Z, Li H, Yan C, Xu B, Hu R, Ma M, et al. A comparative study on the efficacy of fast-track surgery in the treatment of esophageal cancer patients combined with metabolic syndrome. Oncol Lett. 2017;14:4812–6.
- Zhang Z, Zong L, Xu B, Hu R, Ma M, Wei H, et al. Observation of clinical efficacy of application of enhanced recovery after surgery in perioperative period on esophageal carcinoma patients. J buon. 2018;23:150–6.
- Low DE, Allum W, De Manzoni G, Ferri L, Immanuel A, Kuppusamy M, et al. Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS) Society Recommendations. World J Surg. 2019;43:299–330.
- Grant MC, Yang D, Wu CL, Makary MA, Wick EC. Impact of enhanced recovery after surgery and fast track surgery pathways on healthcareassociated infections: results from a systematic review and Meta-analysis. Ann Surg. 2017;265:68–79.
- 36. Bluman LG, Mosca L, Newman N, Simon DG. Preoperative smoking habits and postoperative pulmonary complications. Chest. 1998;113:883–9.
- Mastracci TM, Carli F, Finley RJ, Muccio S, Warner DO. Effect of preoperative smoking cessation interventions on postoperative complications. J Am Coll Surg. 2011;212:1094–6.
- Popping DM, Elia N, Marret E, Remy C, Tramer MR. Protective effects of epidural analgesia on pulmonary complications after abdominal and thoracic surgery: a meta-analysis. Arch Surg. 2008;143:990–9 discussion 1000.

- Brandstrup B, Tonnesen H, Beier-Holgersen R, Hjortso E, Ording H, Lindorff-Larsen K, et al. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. Ann Surg. 2003;238:641–8.
- Hanada M, Kanetaka K, Hidaka S, Taniguchi K, Oikawa M, Sato S, et al. Effect of early mobilization on postoperative pulmonary complications in patients undergoing video-assisted thoracoscopic surgery on the esophagus. Esophagus. 2018;15:69–74.
- Zaouter C, Kaneva P, Carli F. Less urinary tract infection by earlier removal of bladder catheter in surgical patients receiving thoracic epidural analgesia. Reg Anesth Pain Med. 2009;34:542–8.
- Jorgensen H, Wetterslev J, Moiniche S, Dahl JB. Epidural local anaesthetics versus opioid-based analgesic regimens on postoperative gastrointestinal paralysis, PONV and pain after abdominal surgery. Cochrane Database Syst Rev. 2000;4:Cd001893.
- Steinberg JP, Braun BI, Hellinger WC, Kusek L, Bozikis MR, Bush AJ, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the trial to reduce antimicrobial prophylaxis errors. Ann Surg. 2009;250:10–6.
- 44. Committee. ASoA. Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Committee on Standards and Practice Parameters. Anesthesiology. 2011;114:495–511.
- Lewis SJ, Egger M, Sylvester PA, Thomas S. Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and metaanalysis of controlled trials. Bmj. 2001;323:773–6.
- Dag A, Colak T, Turkmenoglu O, Gundogdu R, Aydin S. A randomized controlled trial evaluating early versus traditional oral feeding after colorectal surgery. Clinics (Sao Paulo). 2011;66:2001–5.
- Lassen K, Kjaeve J, Fetveit T, Trano G, Sigurdsson HK, Horn A, et al. Allowing normal food at will after major upper gastrointestinal surgery does not increase morbidity: a randomized multicenter trial. Ann Surg. 2008;247:721– 9.
- Suehiro T, Matsumata T, Shikada Y, Sugimachi K. Accelerated rehabilitation with early postoperative oral feeding following gastrectomy. Hepatogastroenterology. 2004;51:1852–5.
- Guay J, Nishimori M, Kopp SL. Epidural local anesthetics versus opioid-based analgesic regimens for postoperative gastrointestinal paralysis, vomiting, and pain after abdominal surgery: a Cochrane review. Anesth Analg. 2016; 123:1591–602.
- Chen ZX, Liu AH, Cen Y. Fast-track program vs traditional care in surgery for gastric cancer. World J Gastroenterol. 2014;20:578–83.
- Beamish AJ, Chan DS, Blake PA, Karran A, Lewis WG. Systematic review and meta-analysis of enhanced recovery programmes in gastric cancer surgery. Int J Surg. 2015;19:46–54.
- Findlay JM, Gillies RS, Millo J, Sgromo B, Marshall RE, Maynard ND. Enhanced recovery for esophagectomy: a systematic review and evidence-based guidelines. Ann Surg. 2014;259:413–31.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

